Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Targeting the KP.2 strain is expected to provide better protection against COVID-19 based on current data. The 2024-2025 mRNA COVID-19 vaccines will include a monovalent component that corresponds to ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the ...

COVID-19 levels in the United States are high and rising, flu season is approaching quickly, and RSV cases are already ...

In comparison, at its current levels of around $195, AbbVie stock trades at 18x expected 2024 earnings of $10.88 per share. This compares with the 12x average P/E multiple for ABBV seen over the last ...

Pharmaceutical giant Pfizer (NYSE: PFE) and social media platform Snap (NYSE: SNAP) belong to this group: Both have ...

A spokesperson for Hennepin Healthcare explained Pfizer COVID-19 vaccines for patients 5 years old and up have started to arrive at its facilities. A limited schedule of appointments will start ...

The FDA says the latest vaccine formulae "closely targets currently circulating variants" to give better protection against serious COVID-19 impacts.

Pfizer's combined COVID-19 and flu vaccine had mixed Phase 3 results ... patent expiry of the two stellar products. In the below chart, we can see that Eliquis and Prevnar generated around ...

The U.S. Food and Drug Administration recently green-lit new 2024-25 COVID-19 vaccinations ... 2 strain of SARS-CoV-2. These vaccines are manufactured by Moderna and Pfizer, and have been ...